Skip to main content

Table 3 Outcome of patients; Change from baseline to month 12 in H-J classification for patients with ≥ 5% and < 5% decline in VC

From: The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

 

5% decline in VC at month 3

  
 

No

Yes

Total*

P-value

Subjects

194

67

261

 

Mean ± S.D.

0.1 ± 0.7

0.6 ± 0.9

0.2 ± 0.8

0.0002